$1,330.49 general Payment -- AbbVie Inc to Dr. Elizabeth Roberts
Rheumatologist Elizabeth Roberts received $1,330.49 from AbbVie for services related to Eylea.
This page provides a detailed analysis of a $1,330.49 general payment from AbbVie Inc to Dr. Elizabeth Roberts. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $1,330.49 |
| Payment Type | general |
| Payment Nature | Compensation for services other than consulting |
| Pharmaceutical Company | AbbVie Inc |
| Physician | Dr. Elizabeth Roberts |
| NPI Number | 1383576616 |
| Physician Specialty | Rheumatology |
| Location | City, AZ |
| Date of Payment | 2026-03-27 |
| Related Drug/Device | Eylea |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
AbbVie Inc made a $1.3K general payment to Elizabeth Roberts, a Rheumatology specialist in City, AZ. The payment was associated with Eylea. Elizabeth Roberts received a payment of $1,330.49 from AbbVie Inc. The payment was for services other than consulting, specifically related to the drug Eylea. This payment occurred on March 27, 2026, in City, AZ.
Patient Guidance: What This Payment Means for You
If you are a patient of Dr. Roberts, this payment relates to her professional services and may involve discussions about medications like Eylea. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For a Rheumatologist, payments for services other than consulting are common, but the specific drug Eylea is more typically associated with ophthalmology, suggesting a potential need for clarification on the service provided.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- drug-marketing
- rheumatology
- abbvie
- eylea
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $1.3K payment for?
This was a general payment of $1.3K from AbbVie Inc to Elizabeth Roberts, categorized as "Compensation for services other than consulting". It was associated with Eylea. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Elizabeth Roberts accept pharmaceutical money?
Yes, Elizabeth Roberts received this $1.3K payment from AbbVie Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Elizabeth Roberts's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $1.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Rheumatology?
To compare this payment against Rheumatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rheumatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Elizabeth Roberts's relationship with AbbVie Inc?
The payment amount is moderate, falling within a typical range for services rendered. This $1.3K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Rheumatology?
The payment type is 'general', indicating it's not a specific research or educational grant.
What should patients do after learning about this payment?
If you are a patient of Dr. Roberts, this payment relates to her professional services and may involve discussions about medications like Eylea.
What else should I know about this general payment?
The drug mentioned, Eylea, is commonly used in ophthalmology, but its relevance to Rheumatology needs further context.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.